The ultimate goal of the A2M TF is to achieve equal access to medicines for all cancer patients in Europe. To achieve its goal, an open, transparent and continuous dialogue with the pharmaceutical industry is needed.

Meeting Participation
The Task Force will actively participate in events (e.g., meetings, conferences, stakeholder platforms, working groups) if they offer an opportunity to improve our knowledge (information) and share our point of view (advocacy).

- Events must be related to access to cancer medicines (and related sub-topics);
- Events must be organised in such a way that the Task Force will get enough time and space to state its point of view in an impartial way.

The Task Force will keep an inventory of all meetings with pharmaceutical industry.

Continuous Dialogue
The Task Force shall enforce the right, in all collaborations we embark on, to reconsider its participation on a step by step basis. Along the way, we shall evaluate whether continuing the participation will help us to reach our goals. The questions guiding our decision include:

- Was there a fair opportunity to bring the Task Force’s views to the table on previous occasions?
- Are reasonable requests of the A2M TF regarding content and time of its intervention respected?
- Does the Task Force have the opportunity to influence the agenda of following meetings?
- Do reports of previous meetings fairly state our views?
- Are ECL’s conditions re use of the organisation’s name and logo respected?

Restrictions
1. The Task Force will not participate in public events organised by less than three companies or an entity funded by less than three private sponsors. We will only participate in public events organised by industry associations or where a minimum of three companies are involved.

2. The Task Force will not endorse recommendations, vision texts etc. resulting from public events and closed stakeholder meetings in which it participated. If outputs of such events are made public, ECL’s name cannot be mentioned in the publication. Except when:
   - A disclaimer is used stating that ECL’s involvement does not mean endorsement of the content;
   - The content is fully in agreement with the views of the Task Force and putting the name and/or logo was agreed in advance with ECL.

3. ECL’s logo cannot be used on publications, websites or any other communications material of pharmaceutical industry. Exceptions are possible, if the content is fully in agreement with the Task Force’s views and it has been approved by ECL.

4. Members of the Task Force shall not accept funding from the pharmaceutical industry (incl. speaker fees). Exception: Members of the A2M TF can accept travel reimbursement and meals at events organised by industry associations or events with a minimum of three companies involved.